TheraCryf PLC
Company Profile
Business description
TheraCryf PLC is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of unmet medical need within central nervous system (CNS) disorders. The Group's main programme is a novel, benchmark orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol, and other substance use disorders. It also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy, and narcolepsy. The Group also has an oncology programme in glioblastoma with SFX-01. It operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
9
Stocks News & Analysis
stocks
3 charts on Anthropic’s historic IPO filing
stocks
Weight loss drugs not an existential threat to undervalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,046.70 | 77.90 | 0.87% |
| CAC 40 | 7,887.14 | 39.82 | 0.51% |
| DAX 40 | 25,590.77 | 179.93 | 0.71% |
| Dow JONES (US) | 52,377.57 | 15.99 | 0.03% |
| FTSE 100 | 10,686.54 | 80.79 | -0.75% |
| HKSE | 23,041.32 | 170.49 | -0.73% |
| NASDAQ | 26,477.81 | 308.43 | 1.18% |
| Nikkei 225 | 64,048.64 | 780.27 | 1.23% |
| NZX 50 Index | 13,667.69 | 12.58 | -0.09% |
| S&P 500 | 7,722.60 | 45.83 | 0.60% |
| S&P/ASX 200 | 8,923.20 | 73.10 | 0.83% |
| SSE Composite Index | 3,648.30 | 49.22 | -1.33% |